News
Latest valve and structural heart intelligence
Filter by Source
Filter by Tag
Strokes after TAVR remain a problem: Key insights from new registry data
New registry data demonstrates that stroke remains a significant complication following transcatheter aortic valve replacement. The findings highlight the ongoing need for stroke prevention strategies in TAVR patients.
Digest: Stroke is a major adverse event that impacts TAVR outcomes, patient selection, and drives development of cerebral protection devices and anticoagulation strategies.

Milvexian did not reduce ischemic risk in recent ACS
The phase 3 LIBREXIA trial evaluating milvexian, an oral factor XIa inhibitor, was halted early for futility in patients with recent acute coronary syndrome at high risk for recurrent ischemic events. Milvexian added to antiplatelet therapy did not reduce cardiovascular death, MI, or ischemic stroke compared with placebo, though no excess bleeding risk was observed.
Digest: This trial demonstrates that factor XIa inhibition does not provide additional ischemic protection in ACS patients on antiplatelet therapy, though the lack of bleeding signal may inform ongoing anticoagulation strategies in structural heart interventions where thrombotic and hemorrhagic balance is critical.
Enzyme ratio could help cardiologists track risk of stroke, AFib after TAVR
A biomarker enzyme ratio shows potential for predicting stroke and atrial fibrillation risk following transcatheter aortic valve replacement. The diagnostic tool could enable cardiologists to identify high-risk TAVR patients requiring enhanced monitoring or prophylactic intervention.
Digest: Risk stratification biomarkers for post-TAVR cerebrovascular and arrhythmic complications could improve patient selection, personalize antithrombotic strategies, and reduce adverse events in an expanding TAVR population.
SAPT after TAVR linked to key benefits over DAPT, new data confirm
New data confirm that single antiplatelet therapy (SAPT) after transcatheter aortic valve replacement demonstrates key clinical benefits compared to dual antiplatelet therapy (DAPT). The findings support a streamlined antithrombotic strategy that may reduce bleeding complications while maintaining efficacy.
Digest: This evidence could influence anticoagulation management protocols post-TAVR, potentially reducing bleeding risk and healthcare costs while simplifying patient management for the growing TAVR population.